Compare NDLS & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDLS | COCH |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 51.0M |
| IPO Year | 2013 | 2021 |
| Metric | NDLS | COCH |
|---|---|---|
| Price | $13.52 | $0.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 20.4K | ★ 49.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.37 | ★ 7.11 |
| 52 Week Low | $0.47 | $0.36 |
| 52 Week High | $19.00 | $1.89 |
| Indicator | NDLS | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 42.99 |
| Support Level | $12.83 | $0.63 |
| Resistance Level | $13.95 | $0.74 |
| Average True Range (ATR) | 0.73 | 0.03 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 23.12 | 11.33 |
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.